MA27501A1 - Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3 - Google Patents

Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3

Info

Publication number
MA27501A1
MA27501A1 MA28334A MA28334A MA27501A1 MA 27501 A1 MA27501 A1 MA 27501A1 MA 28334 A MA28334 A MA 28334A MA 28334 A MA28334 A MA 28334A MA 27501 A1 MA27501 A1 MA 27501A1
Authority
MA
Morocco
Prior art keywords
adenosine
receptor ligands
imidazoquinoline derivatives
imidazoquinoline
derivatives
Prior art date
Application number
MA28334A
Other languages
English (en)
Inventor
Peter Aranyi
Laszlo Balazs
Maria Balogh
Sandor Batori
Nagy Lajos T
Geza Timari
Kinga Boer
Zoltan Kapui
Endre Mikus
Katalin Gerber
Szeredi Judit Vargane
Katalin Urban-Szabo
Erzsebet Walcz
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA27501A1 publication Critical patent/MA27501A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)

Abstract

L'invention concerne des composés de formule (I), dans laquelle X, Z, R1 -R10, m, n, o, p, r sont, comme dans la description, de préférence de forts antagonistes des ligands récepteurs de l'adénosine A3.
MA28334A 2002-11-15 2005-06-13 Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3 MA27501A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0203976A HUP0203976A3 (en) 2002-11-15 2002-11-15 Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MA27501A1 true MA27501A1 (fr) 2005-08-01

Family

ID=90001561

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28334A MA27501A1 (fr) 2002-11-15 2005-06-13 Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3

Country Status (34)

Country Link
US (2) US7419977B2 (fr)
EP (1) EP1560828B9 (fr)
JP (1) JP4533148B2 (fr)
KR (1) KR20050088291A (fr)
CN (1) CN1332960C (fr)
AR (1) AR041968A1 (fr)
AT (1) ATE325123T1 (fr)
AU (1) AU2003282263B2 (fr)
BR (1) BR0316355A (fr)
CA (1) CA2505910C (fr)
CO (1) CO5690577A2 (fr)
CY (1) CY1105180T1 (fr)
DE (1) DE60305058T2 (fr)
DK (1) DK1560828T3 (fr)
EA (1) EA007595B1 (fr)
ES (1) ES2263039T3 (fr)
HR (1) HRP20050540A2 (fr)
HU (1) HUP0203976A3 (fr)
IL (1) IL168516A (fr)
IS (1) IS2456B (fr)
MA (1) MA27501A1 (fr)
ME (1) MEP19008A (fr)
MX (1) MXPA05005198A (fr)
NO (1) NO20052866D0 (fr)
NZ (1) NZ540029A (fr)
PL (1) PL376837A1 (fr)
PT (1) PT1560828E (fr)
RS (1) RS51320B (fr)
SI (1) SI1560828T1 (fr)
TN (1) TNSN05133A1 (fr)
TW (1) TWI248934B (fr)
UA (1) UA78889C2 (fr)
WO (1) WO2004046146A1 (fr)
ZA (1) ZA200503807B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
KR101820909B1 (ko) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
WO2019055877A1 (fr) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
IL279734B2 (en) 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
EP3937936A4 (fr) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. Inhibition de la protéine de liaison à un élément sensible à l'amp cyclique (creb)
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
BR112023011284A2 (pt) 2020-12-09 2024-02-06 Wellstat Therapeutics Corp Composto de imidazoquinolina com atividade anti-inflamatória, antifúngica, antiparasítica e antineoplásica

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
GB1596652A (en) * 1977-01-20 1981-08-26 Roussel Lab Ltd Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
SE441449B (sv) 1979-02-09 1985-10-07 Roussel Uclaf Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
FR2448541A1 (fr) 1979-02-09 1980-09-05 Roussel Uclaf Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4644002A (en) 1979-02-09 1987-02-17 Roussel Uclaf Imidazo[2,1-C]quinolines, useful as antiallergic agents
CA2336967C (fr) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antagonistes du recepteur de l'adenosine a3
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
JP4077198B2 (ja) * 1999-09-28 2008-04-16 株式会社大塚製薬工場 トリアゾロプリン誘導体、該誘導体を含有する医薬組成物およびアデノシンａ３受容体親和剤
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
BR0115847A (pt) * 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
EP1390349B1 (fr) 2001-05-31 2012-07-25 Sanofi Derives d'aminoquinoline et d'aminopyrridine et leur utilisation comme ligands d'adenosine a3
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en) 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IS2456B (is) 2008-11-15
AU2003282263A1 (en) 2004-06-15
MXPA05005198A (es) 2005-08-18
CN1332960C (zh) 2007-08-22
PT1560828E (pt) 2006-08-31
IS7874A (is) 2005-05-31
NO20052866L (no) 2005-06-13
JP2006515572A (ja) 2006-06-01
IL168516A (en) 2011-05-31
CO5690577A2 (es) 2006-10-31
ATE325123T1 (de) 2006-06-15
JP4533148B2 (ja) 2010-09-01
EA200500830A1 (ru) 2005-10-27
TNSN05133A1 (en) 2007-05-14
CY1105180T1 (el) 2010-03-03
ES2263039T3 (es) 2006-12-01
US7419977B2 (en) 2008-09-02
TW200413369A (en) 2004-08-01
EA007595B1 (ru) 2006-12-29
SI1560828T1 (sl) 2006-08-31
ZA200503807B (en) 2006-08-30
US20050234056A1 (en) 2005-10-20
HRP20050540A2 (en) 2005-08-31
US7709489B2 (en) 2010-05-04
RS51320B (sr) 2010-12-31
RS20050364A (sr) 2007-08-03
HUP0203976A3 (en) 2004-08-30
NZ540029A (en) 2007-01-26
MEP19008A (en) 2010-06-10
DK1560828T3 (da) 2006-09-04
CN1726213A (zh) 2006-01-25
CA2505910A1 (fr) 2004-06-03
KR20050088291A (ko) 2005-09-05
TWI248934B (en) 2006-02-11
EP1560828B1 (fr) 2006-05-03
DE60305058D1 (de) 2006-06-08
WO2004046146A1 (fr) 2004-06-03
CA2505910C (fr) 2010-07-13
HU0203976D0 (en) 2003-01-28
PL376837A1 (pl) 2006-01-09
UA78889C2 (en) 2007-04-25
EP1560828A1 (fr) 2005-08-10
AU2003282263B2 (en) 2009-05-14
HUP0203976A2 (hu) 2004-07-28
NO20052866D0 (no) 2005-06-13
BR0316355A (pt) 2005-09-27
DE60305058T2 (de) 2006-12-14
US20080255110A1 (en) 2008-10-16
EP1560828B9 (fr) 2007-02-14
HK1077819A1 (en) 2006-02-24
AR041968A1 (es) 2005-06-01

Similar Documents

Publication Publication Date Title
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
DK1200418T3 (da) Nematodicide trifluorbutener
TR200000782T2 (tr) Resorsinol türevleri.
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
ES2243579T3 (es) Derivados de pirazolopirideno.
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
NO20034667D0 (no) Arylsulfonamider som antivirale midler
MXPA01008347A (es) Compuestos quimicos.
SE9901077D0 (sv) Novel use
ATE297903T1 (de) Substituierte phenyluracile
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
BR9902084A (pt) Heterociclos.
DE60222465D1 (de) Pyrazolopyridin-derivate als antiherpesmittel
ATE274515T1 (de) Pyrazolopyridinderivate
SE9604582D0 (sv) Novel compounds
DE602004016328D1 (de) 2-imidazo-benzothiazole als adenosin-rezeptor liganden
MXPA04006115A (es) Derivados de imidazoquinolina.
SE9904128D0 (sv) Novel compounds
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri